Cyxone
Business Services · Ireland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
21 Adelgatan, Dublin, South Dublin, 22, ...Phone Number
+46 708882172Website
www.cyxone.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyxone your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cyxone
Click to see if Cyxone had a recent Job posting/layoffs
Cyxone, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cyxone recently announced quarterly report
Check out if Cyxone is spiking on competitors!
Check if Cyxone has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cyxone launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cyxone has new funding data
Recommended Actions
Reach out to Masked Content who joined Cyxone as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Cyxone is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cyxone is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cyxone.
Cyxone Tech Stack
A closer look at the technologies used by Cyxone
Most Recent Scoops
Pain Point
Pain Point, Bankruptcy, Finance
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Left Company
Executive Move
Promotion
Executive Move
Cyxone News & Media
Cyxone AB publishes outcome of rights issue
The subscription period in Cyxone AB’s ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 27.3 percent, including pre-subscription commitments. Cyxone will thus be provided proceeds of approximately SEK 6.3 million before deduction of transaction related costs. Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 6.3 million including pre-subscription commitments oThe subscription period in Cyxone’s rights issue starts today
Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the "Rights Issue") of a maximum of SEK 23 million, with preferential right for the Company's existing shareholders, begins. The purpose of the capital acquisition is primarily to finance development programs with exploratory studies with the drug candidate rabeximod for patients who do not respond well to TNFa inhibitors and to finance development of T20K. The subscription periodCyxone AB publishes investment memorandum
On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of shares (the "Rights Issue"). Prior to the Rights Issue, Cyxone has prepared an investment memorandum containing information about the Company and the Rights Issue, which is now available via the Company's website (www.cyxone.com). The subscription period begins on 1 August 2024 and lasts until 15 August 2024. NOT FOR RELEASE, PUBLICATION ORThe board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
The board of Cyxone AB (publ), corporate no. 559020-5471, ("Cyxone" or the "Company") has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders for a total of approximately SEK 23 million before deductions for transaction costs (the "Rights Issue"). The decision has been made with the support of authorization from the annual general meeting in 2024. The purpose of the capital acquisition is primarily to finance development programs
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyxone
Sign Up For FreeTo access detailed company insights
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19... Read More
